Labopharm Reports Results for Third Quarter F...(he treatment of depression said Mr.Howa...),Health

Date:11/9/2007

he treatment of depression," said Mr. Howard-Tripp. "Trazodone has a proven history of efficacy and we believe that by controlling the blood concentration levels through our Contramid(R) controlled-release technology, we can offer a once-daily formulation with a potentially improved side effect profile that takes advantage of trazodone's unique sedative effects, eliminating the need for adjunctive therapy often associated with other anti-depressants to address related conditions such as poor sleep quality. We look forward to reporting data from our Phase III study in the second quarter of next year."

Other Development Programs

Labopharm continues to advance the development programs for other product candidates in its pipeline, including its programs to develop a twice-daily tramadol-acetaminophen combination formulation and a twice-daily acetaminophen formulation, both of which are based on the Company's proprietary Contramid(R) technology. The Company is currently in the process of preparing for pivotal studies for the tramadol-acetaminophen formulation, which it expects to begin imminently.

Financial Results

Revenue for the third quarter of fiscal 2007 increased to $5.1 million from $3.3 million for the third quarter of fiscal 2006. Product sales increased to $2.8 million from $1.1 million with the increase being the result of higher volumes due to shipments of once-daily tramadol to a larger number of markets in the third quarter of fiscal 2007 compared to the third quarter of fiscal 2006, as well as higher average selling prices in the third quarter of fiscal 2007, primarily as a result of launch of the product in Canada, where selling prices are higher than in Europe. Product sales for the third quarter of fiscal 2007 consisted of follow-on shipments of once-daily tramadol to our marketing partners in Europe for distribution in various markets, as well as initial shipments to Paladin Labs Inc. for distribution in Canada.

Gross marg
'/>"/>

SOURCE Labopharm Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
8. Haemacure Reports Third Quarter 2007 Results
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results